Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB-Guide: T-DXd-based Therapy in First-line HER2+/HR+ Advanced or Metastatic Breast Cancer
NCT07683754Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2026
- Primary completion
- Jul 2030
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab deruxtecan in breast cancer, sponsored by Daiichi Sankyo Co., Ltd.. Started Sep 2026; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07683754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07683754.